BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mazzotta M, Krasniqi E, Barchiesi G, Pizzuti L, Tomao F, Barba M, Vici P. Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer. J Clin Med 2019;8:E254. [PMID: 30781624 DOI: 10.3390/jcm8020254] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Valdivia G, Alonso-Diez Á, Pérez-Alenza D, Peña L. From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review. Front Vet Sci 2021;8:623800. [PMID: 33681329 DOI: 10.3389/fvets.2021.623800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Heo Y, Syed YY. Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer. Targ Oncol 2019;14:749-58. [DOI: 10.1007/s11523-019-00684-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Deng H, Du X, Wang L, Chen M. Six Months vs. 12 Months of Adjuvant Trastuzumab Among Women With HER2-Positive Early-Stage Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Front Oncol 2020;10:288. [PMID: 32266131 DOI: 10.3389/fonc.2020.00288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ryan TD, Nagarajan R, Godown J. Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients. Curr Treat Options Oncol 2019;20:56. [PMID: 31129800 DOI: 10.1007/s11864-019-0658-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Xu Y, Wang L, Pan D, Yan J, Wang X, Yang R, Li M, Liu Y, Yang M. Synthesis of a novel 89Zr-labeled HER2 affibody and its application study in tumor PET imaging. EJNMMI Res 2020;10:58. [PMID: 32495181 DOI: 10.1186/s13550-020-00649-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Khoury K, Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer P, Warren R, Srichai MB, Hofmeyer M, Asch F, Tan M, Isaacs C, Swain SM. Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Res Treat 2021;185:863-8. [PMID: 33400034 DOI: 10.1007/s10549-020-06053-y] [Reference Citation Analysis]
7 Liu G, Qi X, Li X, Sun F. Ginsenoside Rg2 protects cardiomyocytes against trastuzumab-induced toxicity by inducing autophagy. Exp Ther Med 2021;21:473. [PMID: 33767768 DOI: 10.3892/etm.2021.9904] [Reference Citation Analysis]
8 Liu G, Zhang J, Sun F, Ma J, Qi X, Carbone F. Ginsenoside Rg2 Attenuated Trastuzumab-Induced Cardiotoxicity in Rats. BioMed Research International 2022;2022:1-6. [DOI: 10.1155/2022/8866660] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Aulic S, Marson D, Laurini E, Fermeglia M, Pricl S. Breast cancer nanomedicine market update and other industrial perspectives of nanomedicine. Nanomedicines for Breast Cancer Theranostics. Elsevier; 2020. pp. 371-404. [DOI: 10.1016/b978-0-12-820016-2.00016-1] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]